Fernando Diaz, MD
Hematology & Oncology · McAllen, TXNPI 1902333545
Payments from drug & device makers
Across 117 payments — averaging $49.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Daiichi Sankyo Inc.$302
- Gilead$248
- Karyopharm Therapeutics Inc.$224
- AbbVie$198
- Johnson & Johnson$162
- plus $2K from 34 others
What the payments were for
- Travel & lodging$90816%
- Food & beverage$4,27174%
- Education$56010%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 8 | $2,488 |
| Daiichi Sankyo Inc. | 13 | $302 |
| Gilead | 9 | $248 |
| Karyopharm Therapeutics Inc. | 7 | $224 |
| AbbVie | 4 | $198 |
| Johnson & Johnson | 6 | $162 |
| Lilly USA, LLC | 3 | $140 |
| Novartis | 7 | $139 |
| Pharmacosmos Therapeutics Inc. | 2 | $135 |
| Incyte Corporation | 3 | $135 |
| Medtronic | 1 | $130 |
| Exelixis Inc. | 2 | $124 |
| Seagen Inc. | 1 | $100 |
| Galvanize Therapeutics, Inc | 1 | $91 |
| Pfizer | 6 | $86 |
| E.r. Squibb & Sons, L.L.C. | 4 | $84 |
| Sanofi | 3 | $83 |
| Bristol Myers Squibb | 3 | $77 |
| Genentech USA, Inc. | 3 | $71 |
| Merck | 3 | $67 |
| Jazz Pharmaceuticals Inc. | 2 | $65 |
| Integra Lifesciences Corporation | 1 | $64 |
| Caris MPI, Inc. | 2 | $52 |
| Bayer | 2 | $39 |
| Geron Corporation | 2 | $37 |
| Ipsen Biopharmaceuticals, Inc | 2 | $37 |
| Ferring Pharmaceuticals Inc. | 2 | $37 |
| AVEO Pharmaceuticals, Inc. | 2 | $36 |
| Taiho Oncology, Inc. | 2 | $35 |
| Genmab U.S., Inc. | 1 | $29 |
| Tempus AI, Inc | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Eisai Inc. | 1 | $24 |
| Array Biopharma Inc | 1 | $24 |
| Stemline Therapeutics Inc. | 1 | $23 |
| Syndax Pharmaceuticals, Inc. | 1 | $23 |
| Deciphera Pharmaceuticals Inc. | 1 | $23 |
| Agios Pharmaceuticals, Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| GSK | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,739 in reported general payments places this provider in the 45th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mirtazapine | 33 | $1,106 |
| Finasteride | 11 | $304 |
| Atorvastatin Calcium | 17 | $283 |
| Gabapentin | 23 | $192 |
| Sertraline Hcl | 11 | $141 |
| Levothyroxine Sodium | 19 | $120 |
| Losartan Potassium | 16 | $115 |
| Rosuvastatin Calcium | 12 | $60 |
| Metoprolol Succinate | 23 | $50 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in McAllen
- Nurul WahidMcAllen$2.5M
- Elias JabbourHouston$264.1M
- Luhua WangHouston$79.6M
- Courtney DinardoHouston$74M
- Jorge Cortes-FrancoHouston$59.4M
- William WierdaHouston$58.7M
- Koji SasakiHouston$39.2M
- Kyriakos PapadopoulosSan Antonio$18.5M
- Loretta NastoupilHouston$18.3M
- Christopher FlowersHouston$17.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.